Profile Core value Main business Legitimacy Social Responsibility
    Patents Research Direction Technology Strength
  API Intermediates Side chain for Paclitaxel and Docetaxel N-1 stage
  Production management QC Quality System branch factory
 
logn  

username:

 password:

 

  home
 
  Products Center
  API
Paclitaxel (Semi-synthetic)
Paclitaxel (Natural)
Docetaxel Anhydrous
Docetaxel Trihydrate
Cabazitaxel
Irinotecan HCl Trihydrate 99.5%
Etoposide USP31
Palonosetron Hydrochloride
  N-1 stage of Paclitaxel and Docetaxel
7-Troc-Paclitaxel
7,10-di-Troc-Docetaxel
more...
  Main Intermediates
10-Deacetylbaccatin III
Baccatin III
more...
  Side chain for Paclixel semi-Synthetic
(4S,5R)-3-(N-benzoyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
  Side chain of Docetaxel
(4S,5R)-3-(N-tert-butoxycarbony)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
  Side chain for Paclitaxel and Docetaxel
(3R,4S)-3-hydroxy-4-phenyl-2-azetidinone
Ethyl (2R,3S)-3-Phenylisoserine Ester
more...
Your location >>Home>>About us>>profile
 
 
Shanghai Jinhe Bio-Pharmaceutical Co., Ltd. (Abrr. "Jinhe") , founded in March 2002, is a pharmaceutical enterprise dedicated to R&D, manufacturing and marketing anti-cancer APIs and their intermediates. Based on the R&D achievement of Fudan University, we began to undertake the international business of processing Paclitaxel API. After years of effort, we successfully developed Paclitaxel, Docetaxel, Irinotecan, Etoposide etc, from natural extracting anti-cancer products into material source anti-cancer APIs. In recent years, we developed new APIs, such as Cabazitaxel, Palonosetron hydrochloride etc. In 2012, we cooperated with Shanghai Zhongxi Sunve Pharmaceutical Co.,Ltd, (Abrr. "Sunve") became a member of Shanghai Pharmaceuticals Holding Co.,Ltd. (Abrr. "SPH"). Since then, we targeted ourselves as the production base of SPH on oncology products. In 2015, we and Shanghai Huayu Chinese Herbs Co., Ltd. (Abrr. "Huayu") both subsidiaries of SPH, reorganized Dali Zhonggu Yew Biological Co., Ltd. (Abrr. "Zhonggu Biological") by way of investment in cash. This move indicates that SPH will further integrate its oncology drug industry chain and build its advantage in APIs. In January 2017, we achieved GMP certificate on Bulk Drug (Paclitaxel, Docetaxel). We are always committed to be a competitive and responsible company in global pharmaceutical industry.

   
CopyRight(C)2006,Shanghai Jinhe Bio-Pharmaceutical Co.,Ltd. All Rights Reserved. Supported by ChemNet ChinaChemNet Toocle Copyright Notice ChemNet
HOME About us Products R & D Production and QA Contact us CHINESE
北京快三开奖结果 中国体育彩票7位数怎么看 江西11选5 前三组选 波克棋牌哈尔滨麻将 快乐扑克3豹子技巧 追光棋牌安卓版 吉林快3走势图手机版 大吉大利猜生肖 股票软件行情榜 巅峰团队兼职是真的吗 内蒙古十一选五五遗漏一定牛 广西快3单期在线计划 海南环岛赛游戏 重庆彩开奖号码查询 黑龙江十一选五开奖结果定牛 玩游戏赚钱提现微信的 河南地方麻将